Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of olmesartan medoxomil + levamlodipine in adults with essential hypertension inadequately controlled on monotherapy
CTR20250523Phase 3Completed
- Sponsor
- Beijing Fuyuan Pharmaceutical
- Start
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of olmesartan, Levamlodipine in essential hypertension, sponsored by Beijing Fuyuan Pharmaceutical. Started Mar 2025; status: completed.
02
Drugs
olmesartanLevamlodipine
03
Conditions
essential hypertension
Beyond the preview
Go deeper on CTR20250523.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20250523.